JP2020533340A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533340A5
JP2020533340A5 JP2020514284A JP2020514284A JP2020533340A5 JP 2020533340 A5 JP2020533340 A5 JP 2020533340A5 JP 2020514284 A JP2020514284 A JP 2020514284A JP 2020514284 A JP2020514284 A JP 2020514284A JP 2020533340 A5 JP2020533340 A5 JP 2020533340A5
Authority
JP
Japan
Prior art keywords
preparation
saponin
preparation according
sterol
lipopolysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020514284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533340A (ja
JP7339942B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/049832 external-priority patent/WO2019051149A1/en
Publication of JP2020533340A publication Critical patent/JP2020533340A/ja
Publication of JP2020533340A5 publication Critical patent/JP2020533340A5/ja
Priority to JP2023096388A priority Critical patent/JP2023116652A/ja
Application granted granted Critical
Publication of JP7339942B2 publication Critical patent/JP7339942B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020514284A 2017-09-08 2018-09-07 サポニンを含むリポソーム製剤および使用方法 Active JP7339942B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023096388A JP2023116652A (ja) 2017-09-08 2023-06-12 サポニンを含むリポソーム製剤および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556257P 2017-09-08 2017-09-08
US62/556,257 2017-09-08
PCT/US2018/049832 WO2019051149A1 (en) 2017-09-08 2018-09-07 LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023096388A Division JP2023116652A (ja) 2017-09-08 2023-06-12 サポニンを含むリポソーム製剤および使用方法

Publications (3)

Publication Number Publication Date
JP2020533340A JP2020533340A (ja) 2020-11-19
JP2020533340A5 true JP2020533340A5 (enExample) 2021-10-14
JP7339942B2 JP7339942B2 (ja) 2023-09-06

Family

ID=63708462

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020514284A Active JP7339942B2 (ja) 2017-09-08 2018-09-07 サポニンを含むリポソーム製剤および使用方法
JP2023096388A Pending JP2023116652A (ja) 2017-09-08 2023-06-12 サポニンを含むリポソーム製剤および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023096388A Pending JP2023116652A (ja) 2017-09-08 2023-06-12 サポニンを含むリポソーム製剤および使用方法

Country Status (9)

Country Link
US (1) US20200276299A1 (enExample)
EP (1) EP3678695A1 (enExample)
JP (2) JP7339942B2 (enExample)
KR (1) KR102755593B1 (enExample)
CN (1) CN111315406A (enExample)
AU (1) AU2018330165B2 (enExample)
CA (1) CA3078223A1 (enExample)
WO (1) WO2019051149A1 (enExample)
ZA (1) ZA202001487B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
AU2018258070A1 (en) 2017-04-25 2019-10-24 Adjuvance Technologies, Inc. Triterpene saponin analogues
FR3072880A1 (fr) * 2017-10-30 2019-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Formulation liposomale et son utilisation en therapie anti-tumorale
EP3849521A1 (en) 2018-09-14 2021-07-21 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
US11744874B2 (en) 2019-12-20 2023-09-05 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
EP4125816A4 (en) * 2020-04-01 2024-01-10 University of Cincinnati MATERIALS AND METHODS FOR CANCER THERAPY TARGETING AN IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT
DE102021113470B4 (de) 2020-05-26 2025-11-20 Hyundai Mobis Co., Ltd. Leistungshalbleitervorrichtung und verfahren zur herstellung davon
EP4237085A1 (en) * 2020-10-28 2023-09-06 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
CA3173408A1 (en) 2020-12-23 2022-06-30 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
EP4323377A4 (en) * 2021-04-14 2025-04-23 Adjuvance Technologies, Inc. Vaccines
CN116115566B (zh) * 2021-11-15 2025-02-14 上海维洱生物医药科技有限公司 一种七叶皂苷钠脂质体及其制备方法
WO2023184020A1 (en) * 2022-03-28 2023-10-05 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
TW202438104A (zh) * 2022-12-13 2024-10-01 美商輝瑞股份有限公司 誘發針對困難梭狀芽孢桿菌之免疫反應的免疫原性組成物和方法

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US5169763A (en) 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
MC2178A1 (fr) 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
EP0414374B1 (en) 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US6120769A (en) 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE69233639T2 (de) 1991-07-19 2007-05-31 Csl Ltd., Parkville Polynukleotidabschnitt des HPV16-Genoms
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
CA2123612C (en) 1991-11-16 2002-06-25 Michel De Wilde Hybrid protein between cs from plasmodium and h bsag
US6057427A (en) 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
JPH05328975A (ja) 1992-06-02 1993-12-14 Takara Shuzo Co Ltd Ｅ１ａ−ｆ遺伝子
PT647140E (pt) 1992-06-25 2007-12-27 Univ Georgetown Vacinas de papilomavírus
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
ATE296111T1 (de) 1993-03-09 2005-06-15 Univ Rochester Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6106824A (en) 1993-08-13 2000-08-22 The Rockefeller University Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
JP3967769B2 (ja) 1993-11-17 2007-08-29 オーエム・ファルマ グルコサミンジサッカライド、それらの製造法、それらを含む医薬組成物およびそれらの使用
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US7037712B2 (en) 1994-07-26 2006-05-02 Commonwealth Scientific And Industrial Research Organisation DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
AU4270196A (en) 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
JP3844501B2 (ja) 1995-02-08 2006-11-15 タカラバイオ株式会社 癌の制御
WO1996026277A1 (en) 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5993800A (en) 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6309847B1 (en) 1995-07-05 2001-10-30 Yeda Research And Development Co. Ltd. Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
DK0909562T3 (da) 1996-07-03 2005-08-22 Eisai Co Ltd Injektionspræparat indeholdende en lipid A analog og fremgangsmåde til fremstilling deraf
ATE229073T1 (de) 1996-09-06 2002-12-15 Univ California Protein e25a, methoden zu dessen herstellung und anwendung
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
DE19654221B4 (de) 1996-12-23 2005-11-24 Telefonaktiebolaget Lm Ericsson (Publ) Leitungsanschlußschaltkreis
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
ES2248891T3 (es) 1997-02-25 2006-03-16 Corixa Corporation Compuestos para inmunodiagnostico de cancer de prostata y metodos para su uso.
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
ES2227825T3 (es) 1997-04-01 2005-04-01 Corixa Corporation Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
AU740956B2 (en) 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
CA2654522C (en) 1997-08-29 2014-01-28 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
US6749856B1 (en) 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
DE19744249A1 (de) 1997-10-07 1999-04-29 Bosch Gmbh Robert Flüssigkristallzelle
ATE513042T1 (de) 1998-02-05 2011-07-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
KR100797876B1 (ko) 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
WO1999053061A2 (en) 1998-04-15 1999-10-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
JP2002520054A (ja) 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6375944B1 (en) 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
WO2001014544A1 (en) 1999-08-26 2001-03-01 Biovitrum Ab Novel response element
US7084256B2 (en) 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
US6587792B1 (en) 2000-01-11 2003-07-01 Richard A. Thomas Nuclear packing efficiency
WO2001055362A2 (en) 2000-01-31 2001-08-02 The Governement Of The United States Of America, As Represented By The Secretary, Departement Of Health & Human Services, The National Institutes Of Health Hybrid adeno-retroviral vector for the transfection of cells
ATE444372T1 (de) 2000-05-31 2009-10-15 Human Gene Therapy Res Inst Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US6893820B1 (en) 2001-01-31 2005-05-17 The Ohio State University Research Foundation Detection of methylated CpG rich sequences diagnostic for malignant cells
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
WO2003021227A2 (en) 2001-09-05 2003-03-13 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
DE102005032175A1 (de) 2005-07-09 2007-01-18 Krones Ag Behälter-Behandlungsmaschine und Verfahren zum Laden und Entladen einer Behälter-Behandlungsmaschine
ES2300906T3 (es) 2005-07-19 2008-06-16 GEBRUDER HOLZAPFEL GMBH & CO. KG Ayuda de flotacion.
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
BRPI0809926B8 (pt) 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
US8793881B2 (en) 2008-08-15 2014-08-05 Stanley Black & Decker, Inc. Utility knife with blade lock
MX338898B (es) * 2009-02-17 2016-05-03 Glaxosmithkline Biolog Sa Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio.
SI2437753T1 (sl) * 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
KR20130063493A (ko) * 2010-03-26 2013-06-14 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｉｖ 백신
CA2943190A1 (en) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin

Similar Documents

Publication Publication Date Title
Lacaille-Dubois Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review
KR102755593B1 (ko) 사포닌을 포함하는 리포솜 제형 및 사용 방법
JP6261647B2 (ja) 新規組成物
US11324821B2 (en) Triterpene saponin analogues
RU2016141622A (ru) Нетоксичный адъювантный состав, содержащий композицию содержащей монофосфорил-липид а (mpla) липосомы и сапонин
US11951161B2 (en) Methods for inducing an immune response
JP2017515889A5 (enExample)
ES2320971T3 (es) Arqueosomas como adjuvantes y vehiculos para vacunas acelulares para inducir respuestas de linfocitos t cototoxicos.
KR20220140901A (ko) Hpv 백신
US10973900B2 (en) Dried composition
CN117323427A (zh) 脂质体佐剂及其制造方法和应用
WO2016046113A1 (en) Novel methods for inducing an immune response
JP2025510657A (ja) Ｃ型肝炎ウイルス免疫原性組成物およびその使用方法
WO2025031385A1 (zh) 一种免疫增强型铝乳剂、其制备方法和用途
RU2025116186A (ru) Иммуногенные композиции и способы индукции иммунного ответа против clostridioides (clostridium) difficile
JP6026339B2 (ja) 経皮吸収剤用のリポソーム担体
HK40028670A (en) Liposomal formulations comprising saponin and methods of use
HK1105873A (en) Vaccines